Repligen Reports Fourth Quarter and Full Year 2023 Financial

Reports fourth quarter revenue of $156 million and full year revenue of $639 millionContinued strength in orders with fourth quarter book-to-bill ratio of 1.03

Related Keywords

Massachusetts , United States , Germany , Waltham , Ireland , Sweden , Canada , Estonia , Netherlands , France , China , Sondras Newman , , Exchange Commission The , Securities Exchange , Currency Exchange , Revenue Growth , Drug Administration , European Medicines Evaluation Agency , Linkedin , Repligen Corporation , Chief Executive Officer , Fluid Management , Tangential Flow Filtration , Per Share , Investor Relations , Process Analytics , Private Securities Litigation Reform Act , Securities Act , Securities Exchange Act , Exchange Commission , Annual Report , Quarterly Reports , Months Ended December , Second Supplemental Indenture , Sheet Data , Reported Revenue Growth , Organic Revenue Growth , Total Revenue , Base Revenue , Adjusted Income , Adjusted Net Income , Earnings Per Share , Adjusted Earnings Per Share , Adjusted Cost , Adjusted Rd Expense , Income Guidiance , Per Share Guidance , Condensed Consolidated Statements , Restructuring Plan , Region ,